Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.

EMBO Mol Med 2016 Feb;8(2):105-16

Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute The University of Manchester, Manchester, UK

The lack of actionable mutations in patients with non-small cell lung cancer (NSCLC) presents a significant hurdle in the design of targeted therapies for this disease. Here, we identify somatically mutated ABL1 as a genetic dependency that is required to maintain NSCLC cell survival. We demonstrate that NSCLC cells with ABL1 mutations are sensitive to ABL inhibitors and we verify that the drug-induced effects on cell viability are specific to pharmacological inhibition of the ABL1 kinase. Furthermore, we confirm that imatinib suppresses lung tumor growth in vivo, specifically in lung cancer cells harboring a gain-of-function (GOF) mutation in ABL1. Consistent with structural modeling, we demonstrate that mutations in ABL1 identified in primary NSCLC tumors and a lung cancer cell line increase downstream pathway activation compared to wild-type ABL1. Finally, we observe that the ABL1 cancer mutants display an increased cytosolic localization, which is associated with the oncogenic properties of the ABL1 kinase. In summary, our results suggest that NSCLC patients with ABL1 mutations could be stratified for treatment with imatinib in combination with other therapies.

Download full-text PDF

Source
http://embomolmed.embopress.org/content/embomm/early/2016/01
Web Search
http://embomolmed.embopress.org/cgi/doi/10.15252/emmm.201505
Publisher Site
http://dx.doi.org/10.15252/emmm.201505456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734836PMC
February 2016

Publication Analysis

Top Keywords

lung cancer
12
abl1
10
abl1 mutations
8
abl1 kinase
8
mutated abl1
8
somatically mutated
8
nsclc
6
mutation abl1
4
gain-of-function gof
4
cells harboring
4
harboring gain-of-function
4
abl1 consistent
4
gof mutation
4
structural modeling
4
abl1 identified
4
identified primary
4
mutations abl1
4
demonstrate mutations
4
cancer cells
4
modeling demonstrate
4

Similar Publications